Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639741 | 0.81 | APLNR (0.46) | APLNRCRHR1HTR2A | |
| SCHEMBL5427153 | 0.81 | APLNR (0.46) | APLNRALDH1A1MEN1KMT2AERN1 | |
| SCHEMBL10138443 | 0.77 | APLNR (0.53) | APLNRHTR2AALDH1A1CA12CA1 | |
| SCHEMBL10636549 | 0.76 | CA2 (0.64) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL19612492 | 0.74 | CA12 (0.56) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL25062217 | 0.73 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL12936623 | 0.73 | IDO1 (0.60) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL8282093 | 0.73 | CA12 (0.43) | CRHR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL13400663 | 0.72 | LPAR1 (0.42) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL24305884 | 0.72 | CA12 (0.42) | ALDH1A1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210237040-A1 | METAL-IODIDE CATALYTIC SYSTEM FOR DIRECT ETHERIFICATION FROM ALDEHYDES AND/OR KETONES | SPECIALTY OPERATIONS FRANCE (FR) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210237040-A1 | METAL-IODIDE CATALYTIC SYSTEM FOR DIRECT ETHERIFICATION FROM ALDEHYDES AND/OR KETONES | ADH1C, ADH5, ADH1A | APLNR 4837/4885CRHR1 3075/4885HTR2A 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.